β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence
Status:
Unknown status
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Colon and rectal cancer is the second most prevalent malignant disease in the western world,
causing significant morbidity, mortality, and healthcare sources use. Treating colon and
rectal cancer with curative intent generally includes resection of the primary tumor. Despite
its crucial role, surgery by itself induce physiological changes resulting in significant
immune depression and other physiological perturbations, which may in turn play a significant
role in the initiation of new metastases and the progression of pre-existing dormant
metastases. The aim of this study is to assess the use of perioperative medical intervention
using a combination of a β-adrenergic blocker (Propranolol) and a COX2 inhibitor (Etodolac),
in order to attenuate the surgically induced immunosuppression and other physiological
perturbations, aiming to reduce the rate of tumor recurrence and distant metastatic disease.
Phase:
Phase 3
Details
Lead Sponsor:
Sheba Medical Center
Collaborators:
Rabin Medical Center Tel-Aviv Sourasky Medical Center